Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial, Sagar; Α. Dimopoulos, Meletios; Palumbo, Antonio; White, Darrell; Grosicki, Sebastian; Špıčka, Ivan; Walter‐Croneck, Adam; Moreau, Philippe; Mateos, María‐Victoria; Magen, Hila; R. Belch, Andrew; Reece, Donna; Beksaç, Meral; Spencer, Andrew; Oakervee, Heather; Z. Orlowski, Robert; Taniwaki, Masafumi; Röllig, Christoph; Einsele, Hermann; Lung Wu, Ka; Singhal, Anil; F. San Miguel, Jesús; Matsumoto, Morio; Katz, Jessica; Bleickardt, Eric; Poulart, Valerie; C. Anderson, Kenneth; G. Richardson, Paul

doi:10.1056/nejmoa1505654

Public

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Published in New England Journal of Medicine • Jun 2, 2015

Authors:

Sagar Lonial

Meletios Α. Dimopoulos

Antonio Palumbo

Abstract

BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase ...

Subject

Lenalidomide

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!